www.ijarp.com ISSN 2456-9992 Page: 01-26

International Journal Advanced Research Publications

Review Article

Volume: 02
Issue: 04

RIFAMPICIN: A COMPREHENSIVE REVIEW OF A FIRST-LINE ANTI-TUBERCULOSIS DRUG EARLY – ONSET ALZHEIMER'S, CAUSES, SYMPTOMS, AND MANAGEMENT

Devendra Kumar*[1], Noorul Huda[2], Tanya Sharma[3], Dhananjay Mistry[4], Kamalesh Mistry[5], Tusar Ranjan Pati[6]

[1]Research Scholar, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[2]Associate Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[3]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[4]Lecturer, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[5]Assistant Professor, Department of Pharmacy, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

[6]Assistant professor, Dept. Of pharmaceutical Analysis, Nityananda college of pharmacy Balasore Odisha India – 756060.

Article Received: 21 March 2026, Article Revised: 11 April 2026, Published on: 01 May 2026

***Corresponding Author: Devendra Kumar**

Research Scholar, Faculty of Pharmaceutical Science, Mewar University, Gangrar, Chittorgarh 312901, Rajasthan, India.

DOI: https://doi-doi.org/101555/ijarp.5492

ABSTRACT

Among the first line antitubercular agents globally, Rifampicin is considered to be one of the most important agents. Rifampicin was discovered in the 1960s and is a derivative of Streptomyces mediterranei, which was found to revolutionize the treatment of TB, shortening the treatment period considerably and lowering the chances of relapse problems. It is a bactericidal antibiotic that works by blocking Dna-dependent RNA polymerase in the susceptible organisms thus inhibiting the production of RNA and finally causing death of bacterial cells. The main application of rifampicin is combination therapy in treating

tuberculosis to avoid development of resistance. It is also used in the treatment of leprosy, brucellosis and prophylaxis of meningococcal and Haemophilus influenzae infections. Rifampicin is phosphorously incorporated when taken orally, is extensively diffused in the body, and is processed in the liver. It is a strong stimulator of the cytochrome P450 enzymes, which lead to multiple drug interactions. Side effects are hepatotoxicity, gastrointestinal, flu-like syndrome and orange body fluid discolouration.

Because of the high-worldwide prevalence of tuberculosis, especially in such nations as India, rifampicin still finds that group of drugs as a part of national TB control programs. Nevertheless, with the increasing resistance to rifampicin, multidrug-resistant tuberculosis (MDR-TB) is being introduced, which is highly difficult to treat. This review article is a discussion of the chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, clinical uses, dosage, adverse effects, drug interactions, resistance mechanisms, monitoring parameters and the perspectives of rifampicin in the future.

KEYWORDS: Rifampicin; Rifamycin; Anti-tubercular drug; Tuberculosis (TB); *Mycobacterium tuberculosis*; DNA-dependent RNA polymerase; rpoB gene mutation; Multidrug-resistant tuberculosis (MDR-TB); First-line therapy; Bactericidal antibiotic; Cytochrome P450 induction; Drug–drug interactions;

1. INTRODUCTION to Rifampicin

Rifampicin is an antitubercular medicine that has been used as a first-line drug that has revolutionized the control of tuberculosis (TB) in the world. Tuberculosis is a chronic infectious disease which is mainly caused by Mycobacterium tuberculosis; a non-coliform acid fast bacillus that affects mostly the lungs but may also attack other organs like lymph nodes, bones, kidneys and the central nervous system. TB is a significant health issue of people, particularly in developing nations such as India, despite improvement in healthcare. Introduction of rifampicin into anti-TB treatment greatly reduced the treatment time and enhanced the cure, and this is why it was one of the most significant drugs in contemporary management of infectious diseases.

Rifampicin is an antibiotic that is a member of the rifamycin group. It is a semisynthetic analog of rifamycin B, which was first discovered in Streptomyces mediterranei. Rifampicin is a chemically a complex macrocyclic antibiotic with a naphthohydroquinone chromophore that is enclosed by an ansa chain that is made of aliphatic groups. This specific structure gives the drug the ability to enter into the bacterial cells and to perform its pharmacological

effect. It exists in the form of red-orange crystalline powder and is extremely lipid-soluble, thus being able to penetrate the cell membranes and reach the intracellular organisms.



Figure 1

The major mode of action of rifampicin is through inhibition of bacterial DNA-dependent RNA polymerase. Namely, it attaches to the RNA polymerase 2-subunit enzyme of diseased bacteria. Rifampicin attaches to this enzyme, thus stopping the beginning of RNA synthesis. RNA synthesis is a very crucial process involved in protein synthesis and therefore, by blocking RNA synthesis, proteins synthesis in bacteria are inhibited and the cell dies finally. Rifampicin is bactericidal in actively-dividing organisms and also sterilizing to semi-dormant organisms in bacilli. This sterilizing effect especially in treatment of tuberculosis is important since Mycobacterium tuberculosis may remain in the latent form in the macrophages and caseous lesions.

Rifampicin has a wide spectrum. Even though it is most commonly used to treat tuberculosis, it is also operative against other mycobacteria like Mycobacterium leprae, the agent that causes leprosy. Moreover, it shows activity on a number of gram-positive bacteria and given gram-negative organisms. Due to its strong effect and high rate of resistance selection in case of single use, rifampicin is never used as a single agent with the others antitubercular drugs. It is combined with isoniazid, pyrazinamide and ethambutol in the intensive treatment in the course of normal TB treatment. Combination therapy eliminates the development of strains resistant to particular treatment and guarantees the successful elimination of the organism.Rifampicin has one of the greatest advantages in its ability to penetrate tissues.

Because of its lipophilicity, it can penetrate through macrophages, caseous necrotic material and even the blood-brain barrier in inflamed meninges. This is its property which renders it useful in the treatment of tuberculous meningitis and other kinds of extrapulmonary TB. Moreover, rifampicin spreads all around the body fluids and tissues such as saliva, tears, sweat, and cerebrospinal fluid.

Rifampicin is an oral drug that is well absorbed pharmacokinetically. Food however may decrease its absorption hence usually it is advisable to take the drug on an empty stomach. Once absorbed, it is excreted through bile into the feces and it receives hepatic metabolism. The induction of hepatic microsomal enzymes especially the cytochrome P450 enzymes is one of the pharmacological properties of rifampicin that is unique. These enzyme inductions hasten metabolism of a vast number of drugs that are used concurrently and cause drug interactions. Consequently, close observation must be observed when using rifampicin simultaneously with oral contraceptives, anticoagulants, antiretroviral drugs, antiepileptics, and corticosteroids.

The safety profile of rifampicin is normally satisfactory when administered in a proper manner. The hepatotoxicity is one of the most significant adverse effects of its use, though. There is a possibility of elevation of liver enzymes, and seldom, there is severe hepatitis. Other side effects are gastrointestinal disturbances, hypersensitivity reactions, flu-like syndrome, thrombocytopenia, and an orange-red discoloration of urine, sweat, saliva, and tears. The blanching is also non-infectious but can be very disturbing when the patients are not well advised. Thus, the process of patient education is a critical part of rifampicin treatment.

Rifampicin resistance is a severe clinical problem. Resistance is usually brought about by mutations in rpoB gene that encode the 2 subunit of the RNA polymerase. These mutations lower the binding affinity of rifampicin to its target site making the drug inefficient. Rifampicin resistance is usually linked with the resistance of isoniazid, resulting in multidrug resistant tuberculosis (MDR-TB). MDR-TB has complicated treatment regimens and required administration of second-line medications, which are more often more toxic, costly and less effective. Nucleic acid amplification tests are now molecular diagnostic tools that detect rifampicin resistance quickly in order to initiate proper therapy promptly.

Rifampicin is also used in the prophylaxis of some bacteria infections. It is applied in close contacts of meningococcal meningitis and Haemophilus influenzae type b infected patients to eradicate nasopharyngeal carriage. In leprosy, it is used in a combination with other drugs to avoid resistance, and to guarantee annihilation of Mycobacterium leprae.

Rifampicin is felt to be essential in both national and global TB control efforts. Combination formulations of rifampicin and other anti-TB drugs, which are usually administered at a fixed dosage, enhance patient compliance and decreases the occurrence of resistance of monotherapy. Adherence and success of treatment is also increased by the use of Directly Observed Treatment strategies.

Figure 2

2. Rifampicin Pharmacological Profile and Mechanism of Action.

Rifampicin is a bactericidal antibiotic a member of the rifamycin group, and is believed to be one of the strongest first-line medication used in treating tuberculosis. Its pharmacological significance is due to its peculiar mechanism of action, high sterilizing ability and penetration of the intracellular compartments that contain the *Mycobacterium tuberculosis. Its mechanism of action and pharmacological profile are critical in being able to appreciate its central role in anti-tubercular therapy.

Mechanism of Action

Rifampicin mostly acts through inhibition of bacterial DNA-dependent RNA polymerase. RNA polymerase is a fundamental enzyme that performs the transcription which is a process that converts genetic information stored in DNA into messenger RNA (mRNA). This mRNA consequently becomes a protein synthesis template. Bacteria cannot synthesize proteins required to survive and reproduce without the RNA synthesis.

Rifampicin precisely attaches to the 0 -part of the RNA polymerase enzyme. This binding prevents the lengthening of the chains of RNA during transcription. Notably, rifampicin is not capable of stopping the formation of RNA polymerase-DNA complex but the production of RNA following the initiation of transcription. Consequently, this prevents bacterial growth and death of the organism takes place.

Rifampicin has selectivity. It greatly prefers bacterial RNA polymerase as compared to mammalian RNA polymerase. Thus, it suppresses bacterial transcription and does not have a large effect on human cellular transcription, which ensures its therapeutic efficacy with acceptable levels of toxicity.

Bactericidal and sterilizing activity is tested by means of biological testing.<|human|>Bactericidal and sterilizing Activity of biological testing is tested.

Rifampicin is bactericidal i.e. it acts upon bacteria, not only on their growth. This is especially critical with regard to the treatment of tuberculosis since the pathogen Mycobacterium tuberculosis is known to be found in various metabolic forms of existence in the host. A few bacilli in the cells are actively replicating, and others are inactive or semi-inactive within a macrophage or caseous necrotic lesion.

Rifampicin could enter the macrophages and caseous tissue, owing to its lipophilic property. This enables it to counter intracellular organisms. Its sterilizing effect assists in removing the resistant bacilli which would otherwise lead to relapse. Due to this characteristic, the use of rifampicin in the treatment of TB cut down the treatment of 1824 months to 6 months in the treatment of drug sensitive TB.



Figure 3

Spectrum of Activity

Rifampicin is a widely active antimicrobial agent. It is highly active against:

Tuberculosis, the disease commonly known as TB, is the name of the bacteria called Mycobacterium tuberculosis.

- *Mycobacterium leprae*
- Atypical mycobacteria
- Staphylococcus species are gram-positive coccobacillus.
- Neisseria meningitidis
- Haemophilus influenzae

In spite of its activity with a number of bacteria, its most important clinical application is in the treatment of tuberculosis and leprosy. It is also applied to prevent meningococcal and Haemophilus influenzae infections prophylaxis.

Pharmacokinetic Profile

The clinical efficacy of rifampicin is partly attributed to the pharmacokinetic nature of the drug.

Absorption:

The absorption of rifampicin is good following the oral route. Nevertheless, food can reduce its absorption and therefore it is advisable to take the drug when the stomach is empty. The peak plasma concentrations are normally attained between 2 and 4 hours of administration.

Distribution:

After being absorbed, rifampicin spreads in the body. It enters through the lung tissue, liver, kidney, saliva, tears, sweat and cerebral spinal fluid (when meninges are inflamed). It is highly lipid soluble and can therefore gain access to the macrophages and caseous granulomas where the TB bacilli live.

Protein Binding:

Rifampicin is bound to about 80 per cent of the plasma proteins. Even with this excessive protein binding, there is adequate free drug that can be available to perform antimicrobial effects.

Metabolism:

Rifampicin is hepatically metabolized. The liver deacetylates it to an active metabolite. Another notable property of rifampicin is that it induces hepatic microsomal enzymes especially cytochrome P450 enzymes; CYP3A4 and CYP2C9.

Excretion:

The drug is basically released through the feces through the bile. A little bit is excreted via the urine. It has a half-life of 3 to 5 hours, although this can be reduced through considerable use, as a result of enzyme induction.

Enzyme induction and drug interactions are produced by generating a Braden Scale score.<|human|>The generation of a Braden Scale score produces enzyme induction and drug interactions.

The potent effect of rifampicin, as an enzyme inducer, belongs to the number of the most significant pharmacological characteristics. Rifampicin promotes the production of cytochrome P450 enzymes thereby increasing the rate at which most drugs are metabolized, lowering plasma levels and therapeutic efficacy.

Drugs affected include:

- Oral contraceptives
- Warfarin
- Corticosteroids
- Antiretroviral drugs
- Antiepileptic drugs

Due to such interactions, there can be a need to change the dose or substitute treatment. When HIV and TB are co-infected in a patient, the choice of antiretroviral therapy is what should be carefully selected to prevent failure of the treatment.

Pharmacodynamics

Rifampicin is a concentration-dependent bactericidal agent. An increase in the drug concentrations increases the speed of bacterial killing. It shows a post-antibiotic effect, i.e. the growth of the bacteria will be inhibited even at the concentration that is lower than the minimum inhibitory concentration.

The combination therapy is necessary since resistance would be developed at a very fast rate in case of using rifampicin alone. Being used together with isoniazid and other anti-TB medications, it can improve the effect of treatment and prevent the emergence of resistance.



Figure 4

Resistance Mechanism

Rifampicin resistance is mainly caused by mutations of RpoB gene, encoding the 2 nd subunit of RNA polymerase. The mutations change the drug-binding site, and thus, rifampicin is no longer effective in inhibiting the production of RNA. A major indicator of multidrug-resistant tuberculosis (MDR-TB) is rifampicin resistance. These mutations are now detected by rapid mole diagnostic tests that are used to provide correct treatment.

Clinical Significance

Rifampicin is incomplete without its pharmacological profile that would render it ineffective in treating tuberculosis. It has revolutionized the management of TB all over the world because of its ability to kill bacilli quickly, penetrate tissues and reduce therapy time. Its enzyme-inducing effects and possible resistance, however, need close attention and reasonable application.

Altogether, the combination of the bactericidal and sterilizing effect, the mechanism of action of rifampicin, which affects bacterial RNA polymerase, and a wide distribution of the drug throughout the body and its concentration-dependent bactericidal effect paves the way to consider it one of the most potent anti-tubercular drugs. Its pharmacology needs to be properly understood to guarantee safe, efficient, and reasonable therapeutic use.

3. Rifampicin History and Development.

The discovery and development of rifampicin is one of the fallacies in the history of antimicrobial chemotherapy especially in combating tuberculosis (TB). The treatment of

tuberculosis in the pre-introduction of rifampicin was lengthy, complicated and usually not successful. This drug was developed and revolutionized the world approach to TB treatment, increasing the number of treatment days and cure rates.

This was the era of early treatment of Tuberculosis.

Tuberculosis used to be one of the top causes of death in the world before the mid 20 th century. The only treatment available was sanatorium care, rest, nutrition and surgical procedures including lung collapse therapy. With the discovery of streptomycin in 1943, the effective antimicrobial treatment of TB in the form of treatment commenced. Isoniazid and para-aminosalicylic acid drugs followed. Nevertheless, it took 1824 months or more to treat and there was high development of drug resistance.

There was an increasing need to have more potent bactericidal agents that have sterilizing effect. Scientists were interested in the discovery of antibiotics which could enter the macrophages and destroy inactive bacilli leading to the relapse

Discovery of Rifamycins

History of rifampicin Rifamycins were discovered in the late 1950s and they led to the history of rifampicin. In the year 1957, researchers were able to extract a new set of antibiotics using a soil microbe called Stretptomyces mediterranei (which is currently referred to as Amycolatopsis rifamycinica). It was first referred to as the fermentation product, which was named after a French crime movie by the name Rififi, translated as rififi, meaning drug.

The first one was the isolation of Rifamycin B but it did not provide much clinical use because of the poor pharmacokinetic characteristics. Scientists kept on adjusting its form in order to enhance stability, absorption and antimicrobial activity. Various derivatives were prepared through the semisynthetic chemical modifications.

Figure 5

Development of Rifampicin

Rifampicin (or in the United States of America, rifampin) was produced in the mid-1960s as a more stable and orally active analogue of rifamycin SV. The structural alteration improved its lipid solubility and bioavailability rendering it to be oral.

Its safety and efficacy in the treatment of tuberculosis were first tested in clinical trials in 19651966. The outcomes were very encouraging. Rifampicin had shown potent bactericidal action on the bacteria, the Mycobacterium tuberculosis, including semi-dormant ones. It was very protein penetrable unlike the previous drugs, and it demonstrated good accessibility to intracellular structures and tissues.

Towards the end of 1960s, rifampicin was clinically approved in most countries. Its introduction has transformed the treatment of TB.

The effect on Tuberculosis Treatment relates to the fact that AD2 inhibits the effect of acetylinosine triphosphate (AIT) on eradicating TB.<|human|>The effect on Tuberculosis Treatment is that AD2 blocks the action of acetylinosine triphosphate (AIT) in removing TB.

Pre-rifampicin TB therapy entailed long-term therapy- in most cases taking up to two years. The regimen was long and the rates of relapse were high as well as the adherence of the patients.

Combination therapy which included rifampicin enabled:

- Reduction in length of treatment to 6 months.
- Improved cure rates
- Reduced relapse rates
- Increased sterilizing and bacteria-killing effect.

Rifampicin was incorporated in the standard short course chemotherapy regimen, usually referred to as HRZE (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol). This treatment is the gold standard in the treatment of TB today.

Expanding the clinical applications is an important aspect that Lincoln Medical needs.<|human|>Clinical Application Expansion is a critical area of need in Lincoln Medical.

Rifampicin was used in more clinical indications after its success in the treatment of tuberculosis. It was discovered to have an effect against leprosy, which was treated with the drug becoming a central part of the multidrug therapy. It also showed effectiveness in the removal of nasopharyngeal carriage of: *Neisseria meningitidis and Haemophilus influenzae, thus it can be used as a prophylaxis in close contacts.

Its wide antimicrobial spectrum also added to its relevance in the treatment of infectious diseases.

Resistance and Challenges

Although it has been quite successful, the resistance to rifampicin came with time. Researchers found out that the rpoB gene of Mycobacterium tuberculosis had mutations that lowered the drug affinity to the RNA polymerase. Rifampicin resistance frequently occurred in combination with isoniazid resistance to result in multidrug-resistant tuberculosis (MDR-TB).

MDR-TB developed in 1980s and 1990s brought forth emerging challenges. It also promoted the value of combination therapy, treatment adherence and the creation of quick diagnostic tools to identify the resistance at an early stage.

Conceptual design of the derivatives of New Rifamycin.

Newer rifamycin derivatives were developed so as to overcome resistance and enhance pharmacokinetic characteristics and include:

- Rifabutin
- Rifapentine

Such medications provided longer half-life or decreased potential of drug interactions which was advantageous especially in HIV-TB co-infected patients.

The use of rifampentine, e.g., allowed the use of shorter preventive treatments in the case of latent TB infection, which is another contribution to the struggle with TB.

Role in Global TB Control Programs:

This is the role played by the world in the global TB control programs.

Rifampicin came to the spotlight of the world in the efforts to control tuberculosis. Strategies like directly observed therapy programs involved the use of fixed-dose combinations which contained rifampicin to enhance compliance and reduce chances of resistance.

Rifampicin cannot be done away with in those countries that have a high TB burden. The strategies of management of TB have been strengthened due to the rapid development of molecular diagnostic tests, which can identify the presence of rifampicin resistance.

Scientific and Medical Significance Scientifically and medically, the subject under discussion holds significance by revealing the nature of the relationship between the two races, which is assumed to be a consequence of the second world war (Rolle et al 1998).<|human|>Scientific

and Medical Significance Scientifically and medically, the topic in discussion is significant as it exposes the nature of the relationship between the two races which is envisaged to be a result of the second world war (Rolle et al 1998).

The finding of rifampicin is a classic story of the successful development of antibiotics by the use of microbial fermentation and semisynthetic modification. It also shows how natural products can be optimized structurally to give clinically transformative drugs.The fact that rifampicin is an antimicrobial that inhibits bacterial RNA polymerase presented a new mode of action unlike previously used antibiotics that affected cell wall synthesis or protein synthesis. This increased the number of medicines used to treat infectious diseases.



Figure 6

4. Physicochemical Properties and Structure of Rifampicin Chemical Structures

Rifampicin is a semisynthetic analogue of rifamycin and it falls under the category of ansamycin. The chemical structure and physicochemical properties are important factors that affect its pharmacological action, tissue penetration, and efficacy. Knowledge of its structural characteristics gives an insight into its mechanism of action, stability, solubility and drug interaction profile.



Figure 7

Chemical Classification

Rifampicin is classified as:

- A rifamycin derivative
- A macrocyclic antibiotic
- An ansamycin compound

Ansamycin is the name applied to the antibiotics that include an aromatic nucleus bridged with an aliphatic ansa chain. This arrangement creates a big macrocyclic ring that is needed in biological actions.

Chemical Formula and Molecular Weight: There is no relationship between these two measures.<|human|>Chemical Formula and Molecular weight: No association between the two measures exists.

Chemical Formula: $C_{43}H_{58}N_4O_{12}$**

Molecular Weight: 822.94 g/mol**

Its solubility in lipids and capacity to penetrate biological membrane owing to its relatively high molecular weight and complex ring structure is attributed to the fact that it is lipid soluble.

Structural Features

Rifampicin consists of:

1. Naphthohydroquinone Core:

It is the aromatic ring system which gives the chromophore property to rifampicin, making it have its typical red-orange hue.

2. Aliphatic Ansa Chain:

Ansa bridge links two positions of aromatic nucleus that are not adjacent. This chain is essential in attaching to bacterial RNA polymerase.

3. Functional Groups:

- Hydroxyl groups
- Methoxy groups
- Acetyl substituents
- Piperazine ring

These functional groups determine hydrogen bonding, lipophilicity and target enzyme interaction.

Physical Appearance

Rifampicin appears as:

A crystalline powder that is red-orange in color.

- Slightly bitter in taste
- Light-sensitive

The red-orange intense coloration justifies the discolouration of urine, tears, sweat, and saliva in the course of treatment.

Solubility**

Rifampicin has the following solubility properties:

Soluble freely in organic solvents, e.g. methanol and chloroform.

*** Slightly soluble in water**

*** More stable in acidic pH**

It is lipophilic giving rise to increased tissue penetration but reducing aqueous solubility.

Stability

Due to this reason, the rifampicin formulations are commonly kept in thoroughly closed light-sensitive containers. In drug formulation, stability is necessary to ensure the potency of the drugs.

pKa and Ionization

Rifampicin is also ionized functional groups that enable it to be in various ionization states with changes in pH. Its pKa values influence:

- Membrane distribution Distribution across biological membranes
- Binding to plasma proteins

Rifampicin is not entirely ionized at physiological pH and this process allows the drug to enter the membrane.

Lipophilicity

Lipophilicity is one of the most crucial physicochemical characteristics of rifampicin. Lipid solubility High lipid solubility permits:

- Excellent uptake by the macrophages.
- Penetration of caseous necrotic tissue.

Passage across the blood-brain barrier (in particular, in case of inflammation)

The effectiveness against intracellular Mycobacterium tuberculosis is explicable by this property.

Protein Binding

Rifampicin has an affinity of about 80 percent with plasma proteins. Protein binding High protein binding influences:

- Drug distribution
- Half-life

Other drugs with high protein binding can interact with the drug and thereby alter the effect of the drug.

Although protein binding is high, there is sufficient free drug concentration to carry out the action of the antibacterial.

Figure 8

Crystalline forms and polymorphism are twins, since both exhibit crystalline structures with distinct crystal faces.<|human|>Crystalline forms and Polymorphism are twin brothers as they both have crystalline structures with clearly defined crystal faces.

Similar to most antibiotics, rifampicin can be polymorphic, that is, it can occur in other crystalline forms. The variation of polymorphic forms can occur on:

- Solubility
- Dissolution rate

- Stability

In order to have uniform bioavailability, pharmaceutical manufacturers pay close attention to polymorphic form.

The chemical modification and derivatives are also referred to as the chemical derivatives. Semisynthetic change of rifamycin B to rifampicin was done:

- Oral bioavailability
- Stability
- Antimicrobial potency

The further derivatives like rifabutin and rifapentine were subsequently engineered in order to increase half-life and minimize drug interactions.

The relation of Structure to Activity is defined as the probability of an event to occur in a given instance of a specific experiment, by drawing on previously recorded information on those instances.<|human|>The relation of Structure to Activity has been defined as the possibility of occurrence of an event in a certain instance of a particular experiment with the help of already recorded information on the instances.

Rifampicin is a drug that has a close relationship between its chemical structure and biological activity. The ansa chain enables the molecule to precisely insert into the binding spot of the 2 nd unit of bacterial RNA polymerase. Small structural changes may also significantly decrease the binding affinity and antimicrobial activity.

Rifampicin resistance is developed when mutations change the binding site of RNA polymerase and the drug loses its capacity to attach. This shows its particular structure activity relationship.

The color and clinical relevance are assessed by evaluating the effectiveness of the final product in treating the disease (Hogan, 2005).<|human|>Color and clinical relevance are measured through how effective the end product is in the treatment of the disease (Hogan, 2005).

The conjugated aromatic ring of rifampicin is attributed to the red-orange color of the compound. This medically results in harmless discoloration of body fluids which has to be made known to patients in order to avoid needless preoccupation.

The formulation of the business plan requires a thorough evaluation of its purpose, audience, and presentation style.<|human|>Formulation Due to the need to present the business plan, a careful analysis of the purpose, audience, and the style of presentation is important.

The nature of the rifampicin, being sensitive to moisture and light, makes pharmaceutical preparations to ensure that it is not affected. It is commonly available as:

- Capsules
- Tablets
- Syrup formulations

5. Negative Rifampicin Side Effects

Rifampicin can be mainly administered correctly in combination with other drugs in the treatment of tuberculosis and other infections. However, as with all effective antimicrobial agents, it is linked to a number of side effects. The reactions are mild and self-limiting symptoms to severe complications that need medical care. These are the negative effects that one must comprehend to have safe and effective therapy.

1. Hepatotoxicity

The most important and possibly severe side effects of rifampicin are hepatotoxicity. The drug may lead to the increase of liver enzymes (serum transaminases, SGOT and SGPT). Such increases in most situations are mild and reversible. Severe hepatitis however can be experienced especially when rifampicin is administered together with other hepatotoxic compounds like isoniazid and pyrazinamide.

Patients who were at increased risk are:

- Patients that already have liver disease.
- Chronic alcohol users
- Elderly patients
- HIV-infected individuals

Hepatotoxicity has clinical manifestations of jaundice, dark urine, fatigue, abdominal pain, and nausea. During therapy, it is suggested to monitor liver functional tests regularly.

2. Gastrointestinal Disturbances

The common gastrointestinal side effects of rifampicin are:

Nausea

*** Vomiting**

*** Abdominal discomfort**

*** Diarrhea**

These symptoms tend to be mild, and they can be corrected by further treatment. Absorption is enhanced when the drug is taken on an empty stomach but this can enhance gastric irritations among some patients.

3. Discoloration of Body Fluids, Orange-Red.

The orange-red discolouration of urine, sweat, saliva, tears, and sputum is also one of the most typical reactions of rifampicin. This is because of the natural pigmentation of the drug and data of its metabolism. Though it is not harmful, it can be used to stain contact lenses and clothes. Patient counseling is to be done properly to avoid anxiety over this effect.

4. Hypersensitivity Reactions

Allergic reactions can take place although these are not so frequent. These include:

- Skin rash
- Pruritus (itching)
- Fever
- Eosinophilia

In extreme situations, anaphylaxis reactions could occur. In case of a lot of hypersensitivity, the drug must be stopped.

5. Flu-like Syndrome

The intermittent regimens are better observed to cause flu-like syndrome. Symptoms may include:

- Fever
- Chills
- Headache
- Muscle pain

It is believed that this reaction is immune-mediated and is mostly reversible on withdrawal of the drug.

6. Hematological Effects

Rifampicin can result in blood-related abnormalities which include:

Red blood cell (BCs) abnormalities (such as red blood cell anemia, red blood cell sickle cell abnormality, and red blood cell metabolic anemia)

- Hemolytic anemia
- Leukopenia

Thrombocytopenia is uncommon though it can be severe and cause bleeding disposition. Monitoring of the blood count may be required on high-risk individuals on a regular basis.

7. Renal Effects

Acute kidney injury is rare with rifampicin especially during intermittent therapy or in patients who are allergic to the drug. The symptoms can be low urine output and a high level of serum creatinine.

8. Drug Interactions which result in Indirect Effects.

Rifampicin is a potent hepatic enzyme inducer particularly the cytochrome P450 enzymes. This could decrease the efficacy of various drugs including oral contraceptives, anticoagulants, antiretrovirals and antiepileptics. Treatment failure of co-administered drugs may happen although this is not a direct side effect.

6. Side Effects of Rifampicin Adverse Effects.

Rifampicin is widely acceptable on proper combination therapy with tuberculosis and other infections. Nevertheless, as every effective antimicrobial agent, it has a number of unpleasant side effects. Such reactions are mild and self-limiting reactions to rather severe complications which must be addressed in a medical framework. These are the negative effects that should be understood to be effectively and safely treated.

1. Hepatotoxicity** The most critical and possibly severe adverse effect of rifampicin is hepatotoxicity. It is capable of raising liver enzymes (SGOT and SGPT) as a result of using the drug. These gains are reversible and in most instances mild. Nevertheless, cases of severe hepatitis might arise especially when rifampicin is taken as an augmented administration with other hepatotoxic medications like isoniazid and pyrazinamide.

CONCLUSION

Rifampicin is still one of the most important and indispensable medicines used to treat tuberculosis and other mycobacterial infections. Since it was introduced in the 60s, it has revolutionized the way tuberculosis is treated, as it has decreased the treatment period significantly, increased the cure rates, and lowered the relapse rates. It has revealed itself to have a potent bactericidal and sterilization effect on the world against Mycobacterium tuberculosis, therefore becoming an indispensable part of short-course chemotherapy regimens in most countries. It remains an essential part of first-line treatment of drug-sensitive TB even nowadays.

Rifampicin is unique in its mechanism of action (it targets 8 -subunit of bacterial DNA-dependent RNA polymerase) and therefore it is unlike many other antibiotics. It prevents the synthesis of RNAs and thus prevents the production of proteins hence causing cell death in bacteria. This is especially relevant to its action on both actively dividing and semi-dormant bacilli, which is especially important in tuberculosis where the pathogen can be in various metabolic conditions within the tissues of the host. This sterilizing effect is one of the main reasons why a rifampicin-based regimen allows to reduce the therapy to six months, as compared to very high duration of therapy in the pre-discovery period.

Rifampicin has good oral absorption and extensive tissue distribution pharmacokinetically. It is lipophilic, which means that it is able to enter into the macrophages and caseous necrotic lesions where tuberculosis bacilli live. It however exhibits a potent enzyme-inducing ability on cytochrome P450 enzymes posing clinical problems because of many drug interactions. This attribute has to be assessed thoroughly in patients, particularly those taking oral contraceptives, anticoagulants, antiretroviral therapy or antiepileptic drugs.

Despite being generally well tolerated, rifampicin has some adverse effects with hepatotoxicity as the most significant. Liver function should be regularly monitored especially when it is combined with other hepatotoxic agents like isoniazid and pyrazinamide. The gastrointestinal disturbances and the orange discoloration of the body fluids are the other effects that are mild and can be treated through proper counseling. Patient education is very important in adherence and avoiding avoidable anxiety due to the harmless side effects.

The development of rifampicin resistance is one of the most topical issues in the contemporary tuberculosis treatment. Mutation in the gene rpoB lowers the affinity of the drug to bind to the RNA polymerase resulting to the failure of treatment. Multidrug-resistant TB (MDR-TB) is usually linked to rifampicin resistance, and it is treated with more complex

and lengthy treatment regimens that are also more costly. This shows the significance of following the combination therapy strictly and using rapid diagnostic tools to detect resistance at an early stage.

Finally, the significance of rifampicin on the worldwide population health in general and its importance in the treatment of tuberculosis in particular cannot be overestimated. Its usefulness, successful experience and necessity in national and international TB programs highlight its further significance. Nevertheless, it is important to retain its therapeutic value to the future generations by rational utilization, close monitoring, and continuous investigation of the mechanisms of resistance.

REFERENCES

1. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023.
2. World Health Organization. Treatment of tuberculosis guidelines. 4th ed. Geneva: WHO; 2010.
3. World Health Organization. Consolidated guidelines on tuberculosis. Geneva: WHO; 2022.
4. Sharma SK, Mohan A. Tuberculosis: from an incurable scourge to a curable disease. J Indian Med Assoc. 2013;111(5):345-50.
5. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill; 2021.
6. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw Hill; 2018.
7. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee; 2019.
8. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang & Dale's Pharmacology. 9th ed. Elsevier; 2020.
9. Iseman MD. A clinician's guide to tuberculosis. Philadelphia: Lippincott Williams & Wilkins; 2000.
10. Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle. 1985;66(3):219-25.
11. Campbell EA, Korzheva N, Mustaev A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104(6):901-12.
12. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647-50.

13. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis. Clin Infect Dis. 2002;34(3):320-4.
14. Zumla A, Nahid P, Cole ST. Advances in the development of new TB drugs. Nat Rev Drug Discov. 2013;12(5):388-404.
15. Centers for Disease Control and Prevention. Treatment of tuberculosis. MMWR. 2003;52(RR-11):1-77.
16. Nahid P, Dorman SE, Alipanah N, et al. Official ATS/CDC/IDSA clinical practice guidelines. Clin Infect Dis. 2016;63(7):e147-95.
17. Fox W. Short-course chemotherapy for pulmonary tuberculosis. Bull WHO. 1979;57(6):875-80.
18. Grosset JH. Bactericidal activity of rifampicin. Am Rev Respir Dis. 1978;117(4):733-9.
19. Donald PR, Schaaf HS. Pharmacokinetics of rifampicin. Int J Tuberc Lung Dis. 2007;11(7):732-8.
20. Peloquin CA. Therapeutic drug monitoring in TB. Clin Infect Dis. 2002;34(5):702-12.
21. Acocella G. Pharmacokinetics and metabolism of rifampin. Rev Infect Dis. 1983;5(Suppl 3):S428-32.
22. Ellard GA. The pharmacokinetics of rifampicin. Tubercle. 1969;50(3):144-53.
23. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics of rifamycins. Clin Pharmacokinet. 2001;40(5):327-41.
24. Yew WW. Mechanisms of drug resistance in tuberculosis. Respirology. 2006;11(5):604-13.
25. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378(9785):57-72.
26. WHO. Companion handbook to WHO guidelines for TB. Geneva: WHO; 2014.
27. Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis. 2008;12(7):799-804.
28. Saukkonen JJ, Cohn DL, Jasmer RM, et al. Hepatotoxicity of anti-TB therapy. Am J Respir Crit Care Med. 2006;174(8):935-52.
29. Steele MA, Des Prez RM. The role of rifampin in tuberculosis therapy. Chest. 1988;93(2):362-6.
30. Mitchison DA, Davies GR. The chemotherapy of tuberculosis. Int J Tuberc Lung Dis. 2012;16(6):724-32.
31. CDC. Latent tuberculosis infection treatment regimens. Atlanta: CDC; 2020.
32. Villarino ME, Scott NA, Weis SE, et al. Rifapentine vs rifampin for TB prevention. N Engl J Med. 2011;365:2155-66.

33. Peloquin CA, Namdar R, Dodge AA, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother. 1996;40(6):1434-8.
34. WHO. MDR-TB treatment guidelines. Geneva: WHO; 2019.
35. Daley CL, Caminero JA. Management of multidrug-resistant TB. Clin Chest Med. 2019;40(4):775-95.
36. Boeree MJ, Diacon AH, Dawson R, et al. High-dose rifampicin in TB. Lancet Infect Dis. 2015;15(10):1174-82.
37. Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics of high-dose rifampicin. Antimicrob Agents Chemother. 2007;51(7):2546-51.
38. WHO. Rapid communication on rifampicin-resistant TB. Geneva: WHO; 2021.
39. Zhang Y, Yew WW. Mechanisms of drug resistance in TB. Int J Tuberc Lung Dis. 2009;13(11):1320-30.
40. O'Reilly KM, et al. Epidemiology of rifampicin resistance. Lancet Infect Dis. 2017;17(11):e293-301.
41. Van Ingen J, Aarnoutse RE, Donald PR, et al. Why do we use 600 mg of rifampicin in tuberculosis treatment? Clin Infect Dis. 2011;52(9):e194-9.
42. Svensson EM, Svensson RJ, Te Brake LH, et al. The potential for improved rifampicin dosing in tuberculosis. Clin Pharmacokinet. 2018;57(5):557-70.
43. McIlleron H, Wash P, Burger A, et al. Determinants of rifampicin pharmacokinetics in TB patients. Antimicrob Agents Chemother. 2006;50(7):2356-62.
44. Peloquin CA. Pharmacological issues in TB drug therapy. Ann N Y Acad Sci. 2001;953:157-64.
45. Burman WJ, Jones BE. Clinical and radiographic features of TB relapse. Clin Infect Dis. 2001;32(6):892-900.
46. Mitchison DA. Role of rifampicin in modern TB treatment. J Antimicrob Chemother. 1998;42(1):1-6.
47. Acocella G, Pagani V, Marchetti M, et al. Kinetic studies on rifampicin. Chemotherapy. 1971;16(6):356-66.
48. Ellard GA, Humphries MJ, Allen BW. Serum levels of rifampicin in TB therapy. Br Med J. 1974;2(5917):343-6.
49. Grosset JH, Ji B. Experimental chemotherapy of TB. Tubercle Lung Dis. 1998;79(1):1-8.
50. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycosides and rifamycins in TB therapy. Chest. 2004;125(4):1506-12.

51. Telenti A, Honore N, Bernasconi C, et al. Genotypic assessment of rifampicin resistance. J Clin Microbiol. 1997;35(3):719-23.
52. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial resistance in M. tuberculosis. Tuber Lung Dis. 1998;79(1):3-29.
53. Van Deun A, Aung KJ, Hossain MA, et al. Rifampicin resistance detection methods. Int J Tuberc Lung Dis. 2013;17(3):282-9.
54. WHO. Molecular line probe assays for rapid screening of patients at risk of MDR-TB. Geneva: WHO; 2008.
55. Steingart KR, Sohn H, Schiller I, et al. Xpert MTB/RIF assay for pulmonary TB. Cochrane Database Syst Rev. 2013;(1):CD009593.
56. Lawn SD, Nicol MP. Xpert MTB/RIF assay: development and clinical application. Future Microbiol. 2011;6(9):1067-82.
57. Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for MDR-TB. Lancet Infect Dis. 2010;10(9):621-9.
58. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and injectable drugs. Eur Respir J. 2013;42(1):156-68.
59. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for TB. Lancet. 2010;375(9731):2100-9.
60. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of combinations of TB drugs. Lancet. 2012;380(9846):986-93.
61. Boeree MJ, Heinrich N, Aarnoutse R, et al. High-dose rifampicin safety and tolerability. Lancet Infect Dis. 2017;17(10):1046-56.
62. Jindani A, Borgulya G, DePatino IW, et al. Rifapentine and rifampicin comparative trials. N Engl J Med. 2014;371(17):1599-608.
63. Menzies D, Long R, Trajman A, et al. Adverse events with rifampicin or isoniazid therapy. Ann Intern Med. 2008;149(10):689-97.
64. Tiberi S, Scardigli A, Centis R, et al. Classifying new anti-TB drugs. Eur Respir J. 2017;49(3):1601900.
65. WHO. Guidelines for treatment of drug-susceptible TB and patient care. Geneva: WHO; 2017.
66. WHO. WHO operational handbook on tuberculosis. Module 4: Treatment. Geneva: WHO; 2022.
67. CDC. Managing drug interactions in TB treatment. Atlanta: CDC; 2013.

68. Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure-response relationship for rifampicin. Clin Infect Dis. 2007;45(6):806-12.
69. Chirehwa MT, Rustomjee R, Mthiyane T, et al. Model-based evaluation of higher rifampicin doses. Antimicrob Agents Chemother. 2015;59(1):419-27.
70. Alffenaar JW, Gumbo T, Dooley KE, et al. Integrating pharmacokinetics in TB drug development. Clin Infect Dis. 2019;69(2):S93-101.
71. Stagg HR, Lipman MC, McHugh TD, et al. Short-course rifampicin-based regimens. Clin Infect Dis. 2017;65(6):1043-50.
72. WHO. Latent tuberculosis infection: updated recommendations. Geneva: WHO; 2018.
73. Villarino ME, Dooley SW, Geiter LJ, et al. Rifampin preventive therapy for TB infection. Am J Respir Crit Care Med. 1997;155(5):1735-8.
74. Saukkonen JJ, Powell K, Jereb JA, et al. Monitoring for hepatotoxicity during TB therapy. Clin Infect Dis. 2006;43(1):85-92.
75. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line anti-TB drugs. Am J Respir Crit Care Med. 2003;167(11):1472-7.
76. Pym AS, Saint-Joanis B, Cole ST. Molecular basis of rifampicin resistance. Antimicrob Agents Chemother. 2002;46(3):819-27.
77. Zhang Y. Mechanisms of rifampicin resistance in TB. J Antimicrob Chemother. 2005;56(4):733-6.
78. WHO. Global strategy and targets for TB prevention, care and control. Geneva: WHO; 2014.
79. Raviglione M, Sulis G. Tuberculosis 2015: burden and challenges. Lancet. 2016;387(10024):1161-2.
80. Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.